Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma : Melanoma Research

Journal Logo

Short Communications: Clinical Research

Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma

Pigné, Tristana; Lévy, Mariea; Ducharme, Océanea,b; Dutriaux, Carolinea,b; Gerard, Emiliea; Pham-Ledard, Annea,b; Beylot-Barry, Mariea,b; Prey, Sorillaa,b

Author Information
Melanoma Research 33(3):p 252-256, June 2023. | DOI: 10.1097/CMR.0000000000000884

Abstract

BRAFV600 wild-type advanced melanomas quickly reach a therapeutic dead-end, after immunotherapy failure. Even if preclinical studies have suggested sensitivity to MEK inhibitors such as trametinib in NRAS, NF1 or GNA mutated melanoma, therapeutic options are limited for these patients. We present a retrospective monocentric study of 22 patients with advanced melanoma treated by trametinib after immunotherapy resistance. Melanomas harboured NRAS (20), NF1 (1) or GNA11 (1) mutations. For most of them (18), anti-PD1 was associated with trametinib. A disease-control was reported in 36% of patients (8/22), with six stable diseases and two partial responses according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Median progression-free survival was 2 months (1–14) and median overall survival was 6.5 months (2–24). In patients with progressive disease (14/22), dissociated radiologic responses and clinical benefits such as pain reduction were seen in five patients. High blood level of lactate dehydrogenase (LDH) seemed associated with trametinib failure, without significance (P = 0.06). Adverse events (grade 1–3) occurred in 91% of patients during the first weeks of treatment, mainly papulo-pustular rashes (77%), leg oedemas (36%), asthenia (18%) and diarrhoea (14%). This real-life study showed that trametinib may benefit some metastatic melanoma that progressed after chemotherapy and immune checkpoint inhibitors. Objective disease control (partial response or stable disease) using RECIST criteria was observed in 36% of patients. Because of frequent side-effects which can alter the quality of life and the short response duration, this off-label option has to be discussed with the patient. Studies with combination therapy with trametinib to improve relapse-free survival and lower side-effects are ongoing.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid